COMMUNIQUÉS West-GlobeNewswire

Resonant Releases Details of its Breakthrough XBAR Resonator Technology for 5G Mobile Devices
23/10/2018
GOLETA, Calif., Oct. 23, 2018 (GLOBE NEWSWIRE) -- Resonant Inc. (NASDAQ: RESN), a leader in transforming the way radio frequency, or RF, front-ends are being designed and delivered for wireless devices, today released [...]
Aptose to Release Third Quarter Ended September 30, 2018 Financial Results on November 6, 2018
23/10/2018
Conference Call to Be Held Wednesday, November 7, 2018 SAN DIEGO and TORONTO, Oct. 23, 2018 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (NASDAQ: APTO; TSX: APS), a clinical-stage company developing highly differentiated [...]
Tonix Pharmaceuticals to Present at the Dawson James Securities Small Cap Growth Conference
23/10/2018
NEW YORK, Oct. 23, 2018 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix) announced today that Seth Lederman, M.D., President and Chief Executive Officer of Tonix, will present and host [...]
Imprimis Pharmaceuticals’ Subsidiary Melt Pharmaceuticals Initiates Clinical Development Program for its Patented Non-Opioid and Non-Invasive MK Melt™ Conscious Sedation Drug Candidate
23/10/2018
FDA Grants Pre-IND Meeting; Two Investigator-led Studies on Melt Formulations to Commence in Q4 SAN DIEGO, Oct. 23, 2018 (GLOBE NEWSWIRE) -- Melt Pharmaceuticals, a subsidiary of Imprimis Pharmaceuticals, Inc. (NASDAQ: [...]
Beyondspring Provides Operational Update and Second-Quarter 2018 Financial Results
23/10/2018
- Reported Top Line Positive Efficacy and Safety Data from Phase 2 Study 106 Evaluating Plinabulin in Combination With Neulasta for Chemotherapy-Induced Neutropenia (CIN) Prevention - On Track to Report Interim Data [...]
Intra-Cellular Therapies Announces Favorable Safety Profile for ITI-214 in a Phase 1/2 Clinical Trial in Patients with Parkinson’s Disease
23/10/2018
Results show ITI-214 is associated with clinical signs consistent with improvements in motor symptoms and dyskinesias NEW YORK, Oct. 23, 2018 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) today [...]
CureVac Announces First Study Participant Enrolled in Phase I Clinical Trial Testing Prophylactic mRNA Rabies Vaccine
23/10/2018
Trial to provide first-in-human data for CureVac’s novel mRNA-based intramuscular rabies vaccine TÜBINGEN, Germany and BOSTON, Oct. 23, 2018 (GLOBE NEWSWIRE) -- CureVac AG, a fully integrated biopharmaceutical company [...]
XORTX Announces Revision to Polycystic Kidney Disease Clinical Development Plan
23/10/2018
● Shorter Path to XRx-008 Marketing Approval ● CALGARY, Alberta, Oct. 23, 2018 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. (" XORTX " or the “ Company ”) (CSE:XRX; OTCQB:XRTXF), a biopharmaceutical company focused on [...]
NeoGenomics Signs Definitive Agreement to Acquire Genoptix
23/10/2018
FT. MYERS, Fla., Oct. 23, 2018 (GLOBE NEWSWIRE) -- NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of cancer-focused genetic testing services, announced today that it has entered into a definitive agreement to [...]
Cara Therapeutics Appoints Joana Goncalves, M.D., as Chief Medical Officer
23/10/2018
- Former VP of Medical Affairs for Dermatology at Celgene to lead development of KORSUVA™ in dermatological conditions - STAMFORD, Conn., Oct. 23, 2018 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq:CARA), a [...]
BeyondSpring’s Lead Asset, Plinabulin for the Prevention of Chemotherapy-Induced Neutropenia, Has the Potential to Positively Impact Tumor Microenvironment
23/10/2018
Data Demonstrating Plinabulin’s Immune-Enhancing Potential Presented at European Society for Medical Oncology (ESMO) Congress NEW YORK, Oct. 23, 2018 (GLOBE NEWSWIRE) -- BeyondSpring Inc . (NASDAQ: BYSI), a global, [...]
Cyclacel Pharmaceuticals to Present at the Dawson James Small Cap Growth Conference
23/10/2018
BERKELEY HEIGHTS, N.J., Oct. 23, 2018 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC, Nasdaq:CYCCP) ("Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on [...]
Scythian Biosciences Makes Strategic Investment in Verano™ Holdings with $188 Million USD Transaction
23/10/2018
Scythian Invests USD$88 Million in Verano Class B Membership Units Scythian to Sell 3 Boys Farms in Share Exchange for USD$100 Million in Verano Class B Membership Units M&A Identified, Talent and Capital Aligned [...]
BeyondSpring Announces Top Line Positive Efficacy and Safety Data from Phase 2 Study 106 with Lead Asset, Plinabulin, for Chemotherapy-Induced Neutropenia Prevention
23/10/2018
Plinabulin Significantly Reduced Grade 3/4 CIN and Bone Pain When Combined with Neulasta, Compared to Neulasta Monotherapy, in Breast Cancer Patients Receiving High-Risk TAC Chemotherapy Company to Host Conference Call [...]
Tetraphase Pharmaceuticals Announces Positive Data from Post-Hoc Analysis of Phase 3 Trials Demonstrating Efficacy of XERAVA™ (eravacycline) in Obese and Renally Impaired Patients with Complicated Intra-Abdominal Infections
23/10/2018
WATERTOWN, Mass., Oct. 23, 2018 (GLOBE NEWSWIRE) -- Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a biopharmaceutical company focused on developing and commercializing novel antibiotics to treat life-threatening [...]
Capital Senior Living Corporation Announces Release Date for Third Quarter 2018 Financial Results
23/10/2018
DALLAS, Oct. 23, 2018 (GLOBE NEWSWIRE) -- Capital Senior Living Corporation (NYSE:CSU) will host a conference call with senior management to discuss the Company’s third quarter 2018 financial results. The call will be [...]
Alphatec to Report Third Quarter 2018 Financial Results on November 8, 2018
23/10/2018
CARLSBAD, Calif., Oct. 23, 2018 (GLOBE NEWSWIRE) -- Alphatec Holdings, Inc. (“Alphatec” or the “Company”) (Nasdaq: ATEC), a provider of innovative spine surgery solutions with a mission to improve patient lives through [...]
Reminder: C-RAD Web Presentation Interim Report Q3 2018
23/10/2018
Presentation of the report for the first three quarters of the fiscal year 2018: Date: Friday October 26, 2018 / kl. 13:00 CEST Venue: Online Presentation Topic: C-RAD Interim Report Q3 2018 Procedure: Please register [...]
CellaVision AB: Interim report January-September 2018
23/10/2018
Continued strong performance in all regions July 1-September 30, 2018 Net sales increased by 37 % to SEK 84.3 million (61.3). Organic growth increased to 33 % (-11). Operating profit increased to SEK 21.0 million (10.2 [...]

Pages